Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Skye Bioscience Inc (NASDAQ: SKYE) closed the day trading at $1.38 down -4.83% from the previous closing price of $1.45. In other words, the price has decreased by -$4.83 from its previous closing price. On the day, 0.74 million shares were traded. SKYE stock price reached its highest trading level at $1.4899 during the session, while it also had its lowest trading level at $1.37.
Ratios:
For a better understanding of SKYE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.09 and its Current Ratio is at 6.09. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 06, 2025, Cantor Fitzgerald Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $2.
On August 15, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $10.Evercore ISI initiated its Outperform rating on August 15, 2025, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 22 ’25 when Schwab Andrew J. sold 170,449 shares for $3.42 per share. The transaction valued at 582,936 led to the insider holds 57,493 shares of the business.
Schwab Andrew J. sold 60,956 shares of SKYE for $217,613 on Aug 21 ’25. The Director now owns 63,963 shares after completing the transaction at $3.57 per share. On Aug 22 ’25, another insider, 5AM Partners VII, LLC, who serves as the 10% Owner of the company, sold 170,449 shares for $3.42 each. As a result, the insider received 582,936 and left with 57,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SKYE now has a Market Capitalization of 42764020 and an Enterprise Value of -5453723.
Stock Price History:
The Beta on a monthly basis for SKYE is 2.44, which has changed by -0.70700634 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, SKYE has reached a high of $5.96, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is -58.50%, while the 200-Day Moving Average is calculated to be -51.26%.
Shares Statistics:
Over the past 3-months, SKYE traded about 780.84K shares per day on average, while over the past 10 days, SKYE traded about 3203390 shares per day. A total of 30.99M shares are outstanding, with a floating share count of 18.10M. Insiders hold about 41.59% of the company’s shares, while institutions hold 27.37% stake in the company. Shares short for SKYE as of 1759190400 were 2957160 with a Short Ratio of 3.79, compared to 1756425600 on 2738188. Therefore, it implies a Short% of Shares Outstanding of 2957160 and a Short% of Float of 14.34.
Earnings Estimates
Skye Bioscience Inc (SKYE) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.3 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.29 and -$1.61 for the fiscal current year, implying an average EPS of -$1.4. EPS for the following year is -$1.41, with 7.0 analysts recommending between -$0.71 and -$1.84.
